Literature DB >> 7852509

Energy metabolism and substrate oxidation in acromegaly.

A J O'Sullivan1, J J Kelly, D M Hoffman, R C Baxter, K K Ho.   

Abstract

Short term GH administration increases lipid breakdown and oxidation (lipidox) and reduces glucose uptake and carbohydrate oxidation (CHOox). It is not clear whether similar shifts in substrate oxidation occur in acromegaly, and our aim was to investigate this. Using indirect calorimetry, we compared energy expenditure, CHOox, and lipidox in 20 acromegalic patients and 20 normal subjects pair-matched for sex, age, height, and weight. Investigations were performed in the basal state (12-h fast) and during a 75-g oral glucose tolerance test (OGTT). Acromegalic patients had significantly higher fasting glucose levels and greater glucose and insulin responses during an OGTT than normal subjects. Fasting nonesterified free fatty acid and insulin-like growth factor (IGF)-binding protein-1 levels were similar in the two groups, and both were acutely suppressed by oral glucose to the same degree. Basal energy expenditure was significantly greater in the acromegalic patients (1682 +/- 49 vs. 1540 +/- 45 Cal/24 h; P < 0.05), who showed a trend toward higher basal CHOox. Oral glucose resulted in a significantly higher rise in energy expenditure in the normal compared to the acromegalic subjects. During the OGTT, CHOox significantly increased in both groups, but rose to a higher level in the acromegalic patients (177 +/- 10 vs. 138 +/- 9 mg/min; P = 0.004). Oral glucose significantly reduced lipidox in both groups, but lipidox was reduced to a significantly lower level in the acromegalic patients (32 +/- 4 vs. 46 +/- 3 mg/min; P = 0.004). In acromegaly, basal CHOox (r = 0.56; P = 0.01) and postglucose CHOox (r = 0.79; P = 0.0001) were both positively correlated to IGF-I, but not to insulin and/or glucose. In normal subjects, postglucose CHOox was positively correlated to IGF-I. In summary, hyperinsulinemia in acromegaly was associated with higher glucose levels and a blunted thermogenic response to glucose, and displayed no relationship to the pattern of substrate oxidation. CHOox was increased, and lipidox was reduced in acromegaly, and the extent of IGF-I elevation was related to CHOox in the basal and postglucose states. We conclude that 1) the chronic effects of GH excess on substrate oxidation differ from the short term effects of GH administration; 2) impaired insulin action in acromegaly extends to effects on energy expenditure; and 3) IGF-I may be an important regulator of substrate oxidation in acromegaly.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7852509     DOI: 10.1210/jcem.80.2.7852509

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

2.  The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.

Authors:  A J O'Sullivan; L J Crampton; J Freund; K K Ho
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

Review 3.  Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly.

Authors:  David Robert Clemmons
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 4.  Possible effects of an early diagnosis and treatment in patients with growth hormone deficiency: the state of art.

Authors:  Stefano Stagi; Perla Scalini; Giovanni Farello; Alberto Verrotti
Journal:  Ital J Pediatr       Date:  2017-09-16       Impact factor: 2.638

5.  Reduced basal ATP synthetic flux of skeletal muscle in patients with previous acromegaly.

Authors:  Julia Szendroedi; Elisabeth Zwettler; Albrecht Ingo Schmid; Marek Chmelik; Giovanni Pacini; Gertrud Kacerovsky; Gerhard Smekal; Peter Nowotny; Oswald Wagner; Christoph Schnack; Guntram Schernthaner; Klaus Klaushofer; Michael Roden
Journal:  PLoS One       Date:  2008-12-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.